BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Clovis Oncology 

1871 Folsom Street

Boulder  Colorado  80302  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS










 Company News
Clovis Oncology (CLVS) Receives Breakthrough Therapy Designation For Rucaparib For Monotherapy Treatment Of Advanced Ovarian Cancer In Patients With BRCA-Mutated Tumors (Inclusive Of Both Germline And Somatic BRCA Mutations) 4/7/2015 10:07:18 AM
Clovis Oncology (CLVS) Shares Leap as FDA Deems Ovarian Cancer Drug a Breakthrough, Company Preps for ARIEL3 4/7/2015 7:37:52 AM
Clovis Oncology (CLVS) Announces 2014 Operating Results 2/26/2015 11:36:38 AM
Clovis Oncology (CLVS) To Announce Fourth Quarter/Year-End 2014 Financial Results And Host Webcast Conference Call On February 25 2/18/2015 1:46:23 PM
Clovis Oncology (CLVS) To Present At The 2015 Leerink Global Healthcare Conference 2/4/2015 10:28:58 AM
Clovis Oncology (CLVS) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/6/2015 11:32:34 AM
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014 9:21:39 AM
Clovis Oncology (CLVS) Release: Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-Free Survival (PFS) In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 11/19/2014 12:14:36 PM
Clovis Oncology (CLVS) Rises On News Of GlaxoSmithKline (GSK) Oncology Collaboration 11/18/2014 7:59:35 AM
Clovis Oncology (CLVS) Announces First Patient Enrolled In TIGER-1 Study 11/13/2014 10:53:56 AM
12345678910...